FDA — authorised 28 July 2010
- Application: NDA022134
- Marketing authorisation holder: ABBVIE
- Local brand name: LASTACAFT
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
🇺🇸 Lastacaft in United States
FDA authorised Lastacaft on 28 July 2010
Marketing authorisations
FDA — authorised 23 June 2023
- Application: ANDA210659
- Marketing authorisation holder: EUGIA PHARMA
- Local brand name: ALCAFTADINE
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA — authorised 1 March 2024
- Application: ANDA209706
- Marketing authorisation holder: GLAND
- Local brand name: ALCAFTADINE
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA — authorised 2 October 2024
- Application: ANDA209290
- Marketing authorisation holder: ALEMBIC
- Local brand name: ALCAFTADINE
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
Lastacaft in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Lastacaft approved in United States?
Yes. FDA authorised it on 28 July 2010; FDA authorised it on 23 June 2023; FDA authorised it on 1 March 2024.
Who is the marketing authorisation holder for Lastacaft in United States?
ABBVIE holds the US marketing authorisation.